January 21, 2014 | Israeli company Pluristem Therapeutics, which develops placenta-based cell therapies, has announced tthe results from its Phase I/II clinical trial of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle injury. The trial indicated PLX-PAD cells were safe and statistical significance was reached.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments